Suppr超能文献

SARS-CoV-2 奥密克戎 BA.1、BA.1.1、BA.2 和 BA.3 亚谱系的抗体逃逸。

Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages.

机构信息

Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China.

State Key Laboratory of Genetic Engineering, Shanghai Institute of Infectious Disease and Biosecurity, School of Life Sciences, Fudan University, Shanghai, China.

出版信息

Cell Host Microbe. 2022 Aug 10;30(8):1077-1083.e4. doi: 10.1016/j.chom.2022.05.001. Epub 2022 May 8.

Abstract

The SARS-CoV-2 Omicron variant has evolved into four sub-lineages-BA.1, BA.1.1, BA.2, and BA.3-with BA.2 becoming dominant worldwide. We and others have reported antibody evasion of BA.1 and BA.2, but side-by-side comparisons of Omicron sub-lineages to vaccine-elicited or monoclonal antibody (mAb)-mediated neutralization are necessary. Using VSV-based pseudovirus, we report that sera from individuals vaccinated by two doses of an inactivated whole-virion vaccine shows weak to no neutralization activity, while homologous or heterologous boosters markedly improve neutralization titers against all Omicron sub-lineages. We also present neutralization profiles against a 20 mAb panel, including 10 authorized or approved, against the Omicron sub-lineages, along with mAb mapping against single or combinatorial spike mutations. Most mAbs lost neutralizing activity, while some demonstrate distinct neutralization patterns among Omicron sub-lineages, reflecting antigenic differences. Collectively, our results suggest the Omicron sub-lineages threaten the neutralization efficacy of current vaccines and antibody therapeutics, highlighting the importance of vaccine boosters.

摘要

SARS-CoV-2 的奥密克戎变体已经进化成四个亚谱系——BA.1、BA.1.1、BA.2 和 BA.3——其中 BA.2 在全球范围内占主导地位。我们和其他人已经报告了 BA.1 和 BA.2 的抗体逃逸现象,但有必要对奥密克戎亚谱系进行并排比较,以评估疫苗诱导或单克隆抗体 (mAb) 介导的中和作用。我们使用基于 VSV 的假病毒报告说,接种两剂灭活全病毒疫苗的个体血清显示出弱至无中和活性,而同源或异源加强针显著提高了对所有奥密克戎亚谱系的中和效价。我们还提供了针对 20 个 mAb 面板的中和谱,包括 10 个授权或批准的 mAb,针对奥密克戎亚谱系,以及针对单个或组合刺突突变的 mAb 作图。大多数 mAb 失去了中和活性,而一些 mAb 在奥密克戎亚谱系中表现出不同的中和模式,反映了抗原差异。总的来说,我们的结果表明奥密克戎亚谱系威胁到当前疫苗和抗体治疗的中和效果,凸显了疫苗加强针的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb4c/9080084/582d8d711efb/fx1_lrg.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验